Clinical trial · Observational
Asia PDL1 Study Among NSCLC Patients
A Retrospective Non-Interventional Study of PD-L1 Prevalence and Clinical Outcomes for Non-Small Cell Lung Cancer in Asia-Pacific
NCT03037086CI-TRIAL-00031856MEDI-APEXcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
MEDI-APEX is a non-interventional, retrospective, cohort study to characterize PD-L1 expression and to assess the clinical characteristics and outcomes among NSCLC patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced or Metastatic NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- One single cohort
- description
- One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
Primary outcomes (1)
- measure
- Characterization of PD-L1 expression among NSCLC patients
- timeFrame
- from NSCLC diagnosis date between January 2010 and December 2014 until index date, defined as the date of data abstraction
- description
- Characterization of PD-L1 expression among locally advanced, unresectable NSCLC patients (Stage III) and newly diagnosed Stage IV or recurrent metastatic NSCLC patients.
Secondary outcomes (6)
- measure
- Examination of overall survival by PD-L1 status among NSCLC patients
- timeFrame
- from NSCLC diagnosis date between January 2010 and December 2014 until index date, defined as the date of data abstraction
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult male or female (according to age of majority as defined in local regulations). 2. NSCLC diagnosis between 01 January 2010 and 31 December 2014. 3. FFPET collected via core needle biopsy or resection and available in sufficient amount to complete PD-L1 testing. 4. FFPET tissue samples collected for NSCLC original diagnosis determination or for further analysis (e.g. research or treatment purposes) until the index date. 5. Patients with locally advanced or metastatic NSCLC who have initiated 1st line palliative chemotherapy by 31 December 2014. Exclusion Criteria: 1\. Patients with locally advanced NSCLC with resectable disease and treated with curative intent.
References
Publications (0)
Data not yet available
No reference posted for this study.